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M A J O R A R T I C L E
Cultivation of Tropheryma whipplei
from Cerebrospinal Fluid
Matthias Maiwald,1 Axel von Herbay,5 David N. Fredricks,1,3,a Cleber C. Ouverney,1 Jon C. Kosek,2,4
and David A. Relman1,3,4
Departments of 1Microbiology and Immunology, 2Pathology, and 3Medicine, Stanford University School of Medicine, Stanford, and 4Veterans
Affairs Palo Alto Health Care System, Palo Alto, California; 5Department of Pathology, University of Heidelberg, Heidelberg, Germany
(See the editorial by Scheld on pages 797–800.)
Whipple disease (WD) is a systemic disorder caused by the bacterium Tropheryma whipplei. Since the rec-
ognition of a bacterial etiology in 1961, many attempts have been made to cultivate this bacterium in vitro.
It was eventually isolated, in 2000, from an infected heart valve, in coculture with human fibroblasts. Here
we report the isolation of 2 new strains of T. whipplei from cerebrospinal fluid (CSF) of 2 patients with
intestinal WD but no neurological signs or symptoms. One culture-positive specimen was obtained before
treatment; the other was obtained 12 months after discontinuation of therapy, at a time of intestinal remission.
In both cases, 15 passages of the cultures were completed over 17 months. Bacterial growth was measured by
quantitative polymerase chain reaction, which suggested a generation time of 4 days. Staining with YO-PRO
nucleic-acid dye showed characteristic rod-shaped bacteria arranged in chains. Fluorescent in situ hybridization
with a T. whipplei–specific oligonucleotide probe, a broad-range bacterial probe, and a nonspecific nucleic-
acid stain indicated that all visible bacteria were T. whipplei. Scanning electron microscopy and transmission
electron microscopy showed both intracellular and extracellular bacteria. This first isolation of T. whipplei
from CSF provides clear evidence of viable bacteria in the central nervous system in individuals with WD,
even after prolonged antibiotic therapy.
In 1907, George H. Whipple described the postmortem
examination of a patient who had died of a chronic
disease presenting with arthritis, fever, weight loss, and
cough [1]. He observed deposits of fat and fatty acids
in the intestinal mucosa and mesenteric lymph nodes
and named the disease “intestinal lipodystrophy.” Whip-
ple also observed small bacteria in silver-stained sections
of a mesenteric lymph node, but he did not interpret
this finding as causally related to the disease. Subsequent
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reports characterized Whipple disease (WD) as a rare,
chronic, systemic disease, involving predominantly the
intestinal tract but also a variety of other organs, espe-
cially the central nervous system (CNS) [2]. The etiology
remained unclear for 140 years, until a bacterial cause
was suggested by 2 observations: (1) a 1952 report of
successful antibiotic treatment [3], and (2) the 1961 de-
tection, by electron microscopy, of numerous, small, uni-
form bacteria in affected tissues [4, 5]. Both types of
observations were subsequently confirmed and extended
by many others.
Numerous attempts have been made to cultivate the
WD bacterium in the laboratory, but they have either
failed or yielded results that proved erroneous [2]. Strep-
tococcus species, Corynebacterium species, and Haemophi-
lus species are among the organisms so implicated [2].
Cultivation of this bacterium has therefore been a goal
of clinicians and microbiologists for several decades.
Characterization of the WD bacterium at the molecular
level was accomplished during the early 1990s, by poly-
merase chain reaction (PCR) using broad-range primers
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to analyze bacterial 16S rDNA [6, 7]; analysis of the novel se-
quence established a phylogenetic relationship to the actino-
mycetes, and the name “Tropheryma whippelii” was proposed
[7]. In 1997, on the basis of the notion that macrophages are
the cell type most prominently involved in the pathology of WD,
investigators inoculated interleukin-4–deactivated macrophages
with heart-valve tissue affected by WD and reported propagation
of bacteria [8]. However, this finding could not be confirmed in
subsequent studies [9].
Long-term cocultivation of the WD bacterium with a human
fibroblast cell line inoculated with heart-valve tissue was re-
ported by Raoult et al. in 2000 [10]. The infection status of
the fibroblasts was determined by microscopy, by periodic-
acid–Schiff (PAS) staining, and by immunofluorescence, with
the patient’s serum. After inoculation of 1 cm2 of cell mono-
layer, the cultures were expanded to 3750 cm2 of infected cells
over 7 passages within 9 months. After each passage, qualitative
PCR detected DNA of the WD bacterium. The estimated bac-
terial doubling time was 18 days, which is longer than that of
any other characterized bacterium. A second strain was sub-
sequently isolated from a duodenal biopsy specimen [11], and
the species designation was modified to “whipplei” [12]. Taken
together, these reports provide good evidence for in vitro prop-
agation of T. whipplei. Nonetheless, two important types of
data are missing: (1) quantitative assessment of bacterial growth
in vitro, by a molecular method, and (2) physical association
of the T. whipplei 16S rRNA sequence with cultivated bacterial
cells, by fluorescent in situ hybridization (FISH). The latter has
been proposed as an important link between bacterial sequence
and visible cells, especially when new taxa are described [13,
14]. Furthermore, the presence of viable T. whipplei bacteria
has not been established in the CNS of individuals with WD.
The availability of two cerebrospinal fluid (CSF) samples with
large numbers of WD bacteria provided an opportunity to
isolate new strains of T. whipplei and address all of these im-
portant issues.
PATIENTS, MATERIALS, AND METHODS
Patients and specimens. This work was approved by the
Stanford University Administrative Panel on Human Subjects
in Medical Research. CSF from 2 patients was used in these
cultivation studies. Both patients presented with intestinal WD
that was diagnosed by histopathology and by PCR analysis of
T. whipplei 16S rDNA. Case 1 was a 74-year-old German man;
the CSF specimen was obtained for the purpose of staging,
before the initiation of therapy. The patient had no neurological
symptoms or signs. Case 2 was a 52-year-old German woman;
staging examinations by PCR analysis of T. whipplei in CSF
[15] revealed CNS infection, but the patient had no neurolog-
ical symptoms or signs. The patient was treated with an initial
course of 2 weeks of penicillin plus streptomycin, followed by
1 year of oral cotrimoxazole. The CSF specimen used for culture
was obtained for the purpose of monitoring response to ther-
apy, 24 months after diagnosis and 12 months after discontin-
uation of antibiotics. At that time, results of PCR analysis of
T. whipplei 16S rDNA of duodenal tissue were negative, and
histology showed remission, in accordance with published cri-
teria [16]. Diagnostic PCR analysis of T. whipplei 16S rDNA
[15] showed strongly positive results for the CSF specimens
from both patients, and the amplified sequence was completely
homologous to the T. whipplei 16S rDNA (GenBank accession
number X99636).
Cultivation methods. Cell cultivation on human fibro-
blasts was performed essentially as described elsewhere [10–
12], with the following modifications: HEPES buffer (12.5 mM)
was used in the medium, and fetal-calf-serum content was
reduced from 10% to 1%, after confluent cell monolayers were
obtained and before inoculation with bacteria. MRC-5 primary
human embryonic lung fibroblasts (CCL-171; American Type
Culture Collection) were cultivated in 25-cm2 tissue-culture
flasks (5-mL medium) and were inoculated with 500 mL of
original CSF. Initial passages of the cultures were performed in
25-cm2 flasks; 75-cm2 flasks (25 mL) and 150-cm2 flasks (35
mL) were later used for large-scale cultures. Each passage of
the cultures involved inoculation of 20%–25% of the volume
of supernatant onto new fibroblast monolayers after 4–6 weeks
of incubation. Medium was changed infrequently: during the
first passage, the medium was changed only after 3 weeks, and,
during subsequent passages, the medium was either not
changed or changed only after ∼4 weeks of incubation. Begin-
ning with the 13th passage, both MRC-5 cells and primary
human foreskin fibroblasts (a gift from E. S. Mocarski, Stanford
University) were used in parallel, for cultivation.
For quantitative measurement of bacterial growth, cell
monolayers were cultivated in 6-well tissue-culture plates (9.5
cm2/well) containing 2 mL of medium. On day 0, duplicate
wells were inoculated with 0.5 mL of vigorously vortexed cul-
ture supernatant from a flask containing infected material. The
contents of these wells were harvested on days 1 and 28 after
inoculation: first, 1.25 mL of culture supernatant was removed,
and then the cell monolayer was removed by a cell scraper and
was harvested together with the residual 1.25 mL of superna-
tant. Both portions were frozen (80C) before analysis.
PCR. Tissue-culture supernatant or cell monolayers were
centrifuged (18,000 g for 10 min), and DNA from the pellet
was extracted as described elsewhere [15, 17]. To detect the
presence of T. whipplei 16S rDNA, qualitative PCR using prim-
ers whip1 and whip2 [17] was performed; for bacterial iden-
tification, PCR using broad-range primers 8FPL plus 806R and
515FPL plus 1492RPL to analyze bacterial 16S rDNA [18].
Quantitative competitive PCR was performed according to
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published protocols [19] and used the primers whip1 and
whip2 [17] and a synthetic internal-standard molecule. This
molecule (the “mimic”) was constructed by PCR, according to
instructions from the Clontech PCR mimic-construction kit.
Composite primers were designed on the basis of the sequence
of the Bordetella bronchiseptica filamentous hemagglutinin gene,
fhaB [20], and T. whipplei 16S rDNA, so that the mimic con-
sisted of a 217-bp sequence including whip1 and whip2 primer
sequences at its ends. As a result, the mimic was easily distin-
guished, on the basis of size, from the 267-bp 16S rDNA am-
plification product (the “target”) of T. whipplei. The prod-
uct from T. whipplei and the mimic were each cloned into the
TA vector (Invitrogen), plasmid DNA was extracted and quan-
tified, and stock solutions containing 108 copies of each plasmid
molecule/mL were prepared. Serial dilutions of the mimic mol-
ecule were used as internal standards in the PCRs, and serial
dilutions of the T. whipplei product were used as quantitative
references in control reactions. Samples from culture were in-
itially tested against 10-fold dilutions of the “mimic,” and then,
for more accurate measurement, against 2-fold dilutions. The
mimic concentration that, in agarose-gel electrophoresis, gave
DNA-band intensity equal to that of the T. whipplei prod-
uct was used to estimate the number of copies of T. whipplei
rDNA in the sample.
Nucleic-acid staining. Nucleic acids in cultivated material
were stained directly with YO-PRO-1 fluorescent dye (Molec-
ular Probes). Culture supernatant was fixed in 3.7% formalde-
hyde, spotted onto glass slides, and air-dried. The slides were
then overlaid with 2 mM YO-PRO-1 in water, incubated for 15
min, rinsed with water, immersed for 15 min in water, rinsed
again, air-dried, and mounted with Vectashield mounting fluid
(Vector Laboratories) and a coverslip (all steps were performed
in the dark).
FISH. FISH was performed essentially as described else-
where [21], with some modifications. In brief, culture super-
natant was centrifuged (10,000 g for 10 min), and the pellets
were resuspended in 1  PBS, mixed with an equal volume of
ethanol (final concentration, 50%), spotted onto Teflon-coated
10-well slides (Erie Scientific), and air-dried, at 45C, on the
wells. The samples on the slides were then fixed by incubations
of 3 min each in 50%, 80%, and 96% ethanol. Hybridization
was performed for 2 h at 46C, with a solution containing 5
 SET, 1% SDS, 10% dextran, 0.2% bovine serum albumin,
0.1 mg polyadenosine/mL, and 5 mg of labeled probe/mL. The
slides were then washed 3 times, for 10 min at 46C, with 0.2
 SET at 46C, rinsed with water, stained with 1 mM YO-PRO-
1 in 1  SET as described above, rinsed again, and mounted
with Vectashield and coverslips. The following oligonucleotide
probes were used: the T. whipplei–specific probe Tw16S-652
(5′-TTCCGCTCTCCCCTATCGCACTCT), the negative-control
probe Tw16S-Cnt (5′-AAGGCGAGAGGGGATAGCGTGAGA)
[21], the broad-range bacterial probe Eub16S-338 (5′-GCTGCC-
TCCCGTAGGAGT) [22], and the probe HGC69a (5′-TATAGT-
TACCACCGCCGT) for gram-positive bacteria with high G+C
content [23]. Tw16S-652, Tw16S-Cnt, and HGC69a were labeled
with the fluorophore Cy-3, and probe Eub16S-338 was labeled
with Cy-5. Cultures of “Corynebacterium aquaticum” (ATCC
14665), Cellulomonas cellulans (ATCC 27402), and Agromyces
ramosus (ATCC 25173)—all Actinobacteria—were used as bac-
terial controls. Slides were viewed and images were recorded by
use of a BioRad MRC-1024 Laser Scanning Confocal Imaging
System, as described elsewhere [21].
Electron microscopy. Cell monolayers were cultivated on
round, 18-mm glass coverslips in 12-well (4-cm2) tissue-culture
plates. Four weeks after inoculation, the medium was removed,
and the cells were fixed, for 2 days, with 1.5% glutaraldehyde
that was buffered to pH 7.3 by sodium cacodylate and that was
made isotonic by the addition of sucrose. For scanning elec-
tron microscopy (SEM), the coverslips with cells and bacteria
were dehydrated with alcohol and a critical-point bomb, were
sputter-coated with 100-A˚ gold, and then were examined by
use of an Hitachi S-2400 scanning electron microscope oper-
ating at an accelerating voltage of 15 kV. For transmission elec-
tron microscopy (TEM), the monolayers were postfixed, for 1
h, in 2% buffered osmic acid, dehydrated with alcohol, and
embedded in epoxy resin. Sections were cut at 50-nm thickness,
were stained serially with uranyl acetate and lead hydroxide,
and then were examined by use of a Phillips 200 electron mi-
croscope operating at an accelerating voltage of 75 kV.
Strain deposition. The isolate from patient 2 (strain
TW08/27) has been deposited in the American Type Culture
Collection (ATCC culture number pending).
RESULTS
Six weeks after inoculation of MRC-5 primary human embry-
onic lung fibroblast monolayers with CSF from cases 1 and 2,
qualitative PCR used to test for T. whipplei in culture super-
natants from the 2 infected monolayers gave positive results.
Cellular and bacterial material from 5 mL of supernatant was
then concentrated, by centrifugation, in 1 mL and then was
inoculated onto fresh monolayers in 25-cm2 flasks. On days 1
and 15 after this passage, 100 mL of supernatant was collected
and analyzed by quantitative PCR. A “low-resolution” quanti-
tative-PCR analysis (using 10-fold dilutions of the mimic) in-
dicated an increase in rDNA copy number, from 105/mL (CSF
of case 1) and !105/mL (CSF of case 2) on day 1 to 106/mL
(in both cases) on day 15. Before inoculation, the original CSF
specimens had shown copy numbers of 104/mL (case 1) and
!104/mL (case 2), by the same PCR. In the subsequent, similar
passage, supernatant from both cultures was stained with YO-
PRO and showed small, rod-shaped bacteria in a characteristic
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Figure 1. Photomicrograph of culture supernatant stained with YO-PRO nucleic-acids dye. A, Strain TW09/02 in third passage (original magnification,
3000). B, Strain TW08/27 in ninth passage (original magnification, 5000). Scale bars represent micrometers.
chainlike arrangement (figure 1A). Culture supernatant was
also examined by PCR using broad-range primers to analyze
bacterial 16S rDNA, in an assay that targets a 1443-bp region
of the 16S rDNA. Direct sequencing of PCR products revealed
unambiguous readings; the sequence from case 1 was a perfect
match to that of T. whipplei [24]; the products from case 2 had
only 2 nucleotide mismatches, in positions where they would
not affect the 16S rRNA structure.
A total of 15 passages were performed with both cultures,
over a period of 17 months. Beginning with the 13th passage,
human foreskin fibroblasts were used in parallel with MRC-5
cells, because they appeared to form more-coherent monolayers
and remained morphologically unaltered over longer incuba-
tion times. Cultures were regularly checked for the presence of
bacteria, by staining the supernatant with YO-PRO; this was
done at each passage, usually between the fourth week of in-
cubation and the time of transfer to a new cell monolayer, and
showed characteristic-looking bacteria (figure 1B). The strain
from case 1 was designated “TW09/02,” the strain from case
2 “TW08/27.” The cultures were expanded to 40 flasks (150
cm2 each) for strain TW09/02 and to 60 flasks for strain TW08/
27. PCR analysis of broad-range bacterial 16S rDNA was re-
peated with both strains after their 15th passage, with the same
results. Material from the 60 flasks with strain TW08/27 was
harvested, and bacterial DNA was extracted and used for a
genome-sequencing project [25] (see the http://www.sanger.ac
.uk/Projects/T_whipplei/ Web site).
Quantitative-PCR studies (see Patients, Materials, and Meth-
ods) were performed again after the 11th passage, using 10-
fold and, subsequently, 2-fold dilutions of the mimic (figure
2). Data from supernatants and data from combined fractions
(supernatant plus cell monolayer) harvested on days 1 and 28
after inoculation were compared (table 1). T. whipplei 16S
rDNA copy numbers were ∼100-fold greater on day 28 than
they were on day 1. In addition, rDNA copy numbers in the
combined fractions were ∼10-fold greater than those measured
in the supernatants alone. These data suggest that, on average,
the bacteria have completed 7 divisions during the intervening
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Figure 2. Agarose gel showing results of polymerase chain reaction (PCR) in cultures in 6-well plates (see Patients, Materials, and Methods), for
combined fractions (supernatant plus cell monolayer) from strain TW08/27, on days 1 and 28 of incubation, tested against initial 10-fold dilutions of
the “mimic” molecule. A positive control with the cloned Tropheryma whipplei “target” (103 copies) was also used. The copy numbers of mimics and
targets used in a 50-mL PCR are given. Because of dilution factors, the calculated copy number per milliliter of culture material (table 1) is 1.5 log
higher than the copy number used in a 50-mL PCR. M, molecular-weight marker.
Table 1. Results of quantitative polymerase chain reaction, for
the 2 Tropheryma whipplei strains from cultures in 6-well plates
(see Patients, Materials, and Methods).
Day after
inoculation
Strain TW09/02 Strain TW08/27
Supernatant
Combined
fraction Supernatant
Combined
fraction
1 5  103/mL 5  104/mL !5  103/mL 2  104/mL
28 8  105/mL 8  106/mL 5  105/mL 5  106/mL
NOTE. Both the culture supernatants (1.25 mL) and the combined frac-
tions (1.25 mL), the latter of which consisted of supernatant plus cell mono-
layer, were tested during the 11th passage on each of the 2 days.
27 days, which corresponds to a bacterial generation time of
∼4 days. To confirm the specificity of the quantitative-PCR
results, a target band from this assay was sequenced, for both
strains; this sequence was identical to the 16S rRNA sequence
of T. whipplei.
For both strains, FISH experiments with culture supernatant
were performed after the 12th and 15th passages. All visible
bacteria in supernatants hybridized with the T. whipplei–specific
probe Tw16S-652, the broad-range bacterial probe Eub16S-
338, and the actinobacterial probe HGC69a but not with the
negative-control probe Tw16S-Cnt. All bacterial control strains
hybridized with Eub16S-338 and HGC69a, none hybridized with
Tw16S-Cnt, and only “C. aquaticum” hybridized, very faintly,
with Tw16S-652, as described elsewhere [21]; this faint signal
was easily distinguishable from the much-brighter signal in the
2 CSF cultures. Triple-label experiments, with YO-PRO, Tw16S-
652, and Eub16S-338, revealed colocalized staining patterns with
the 3 labels, for all bacteria in both cultures (figure 3), indicating
a homogenous population of (T. whipplei) bacteria.
Electron microscopy of culture material from both strains
was performed after the 14th passage. SEM showed intact
extracellular bacteria (figure 4A), and TEM showed well-
preserved bacteria both in extracellular locations and within
the cytoplasm of healthy-appearing fibroblasts (figure 4B).
DISCUSSION
The results of the present study indicate that viable T. whipplei
strains are found in the CSF of patients with WD and that they
can be propagated in the presence of human fibroblasts in
culture. These data confirm and expand on the findings re-
ported by Raoult et al. [10–12]. They also provide the first
quantitative measurement of the growth of T. whipplei in vitro.
A previous report [8], describing the growth of T. whipplei in
interleukin-4–deactivated macrophages, has been not con-
firmed, either by us (M.M. and D.A.R., unpublished results)
or by other investigators [9].
Our data also document the first cultivation of T. whipplei
from CSF samples. CSF is ideally suited for such studies, since
it is a relatively simple fluid that is normally sterile. The ex-
amination of CSF has special relevance for diagnostic testing
for WD, because (1) bacteria appear to invade the CNS early
in the disease and (2) late manifestations affecting the CNS
pose a significant threat to patients [2, 15]. This is illustrated
by a number of published cases with symptomatic CNS disease,
cases in which bacteria appeared to have been eradicated from
the intestinal mucosa after therapy [2, 15, 17, 26–29]. One
noteworthy case presented with severe insomnia as the only
symptom 8 years after intestinal WD had been diagnosed and
treated; at that time, results of intestinal/histological exami-
nation and PCR analysis of intestinal tissue were negative but
PCR analysis showed that CSF was positive for T. whipplei [29].
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Figure 3. Photomicrographs after fluorescent in situ hybridization with strain TW08/27 from the 14th passage of the cultures, for dual hybridization
with probes Tw16S-652 and Eub16S-338, followed by YO-PRO stain. A, YO-PRO stain (nonspecific DNA stain) viewed with the fluorescein isothiocyanate
channel. B, Probe Tw16S-652 (Tropheryma whipplei specific) viewed with the Texas Red channel. C, Probe Eub16S-338 (bacterial broad range) viewed
with the Cy-5 channel (original magnification, 2000). Scale bar represents micrometers.
Often, manifestations of T. whipplei in CNS respond only par-
tially to antibiotics and have a poor prognosis.
A previous study examined CSF samples from 24 patients
with WD that were obtained at various times before and after
therapy [15]; even in neurologically asymptomatic patients,
PCR results were positive for the presence of T. whipplei in 7
of 10 cases before therapy and in 3 of 11 cases after therapy.
These data indicate that the bacterium or its components are
commonly present in the CNS of patients with intestinal WD
and that, even in the presence of prolonged therapy with an-
tibiotics, bacterial clearance may be delayed or uncertain. Fur-
thermore, the data underscore the importance of using anti-
biotics that cross the blood-brain barrier. The isolation of 2 T.
whipplei strains from CSF supports these concepts and em-
phasizes the importance of PCR-based, sensitive approaches
for the detection and monitoring of CNS infection. The pres-
ent study provides new evidence of viable T. whipplei in the
CNS of patients with WD, even in the absence of neurolog-
ical symptoms, and demonstrates that the bacterium can persist
in a viable state, even after 1 year of therapy and intestinal-
disease remission.
Quantitative measurement of bacterial growth is an impor-
tant contribution to the evolving story of the propagation of
T. whipplei ex vivo. The use of an internal standard (i.e., a
mimic) avoids the potential problems of other types of PCR
assays, in which PCR inhibitors might interfere with quanti-
fication [19]. Our calculated doubling time of 4 days differs
from the previously reported time of 18 days, which was based
on semiquantitative microscopic assessment of inclusions in
fibroblast monolayers, inclusions that were shown to be positive
for T. whipplei [10] when the PAS reagent was used, but it is
still among the longest observed doubling times for any bac-
teria. This difference might be due either to the different mea-
surement methods or culture conditions or to the differences
between T. whipplei strains. Knowledge of the generation time
is clinically relevant; with a doubling time of 4 days, a typical,
14-d intravenous therapy–induction period [30] spans only 3
replication cycles and thus might have to be reconsidered.
Bacterial morphology and the chainlike arrangement were
distinctive when revealed by YO-PRO staining (figure 1). FISH
now integrates, for the first time, bacterial morphology and the
16S rRNA sequence of T. whipplei. A previous study with sec-
tions from intestinal biopsy specimens did not resolve individ-
ual bacteria, probably because of high bacterial density and the
thickness of the sections [21]. Triple-label experiments in the
present study (figure 3) showed that nonspecific staining of
DNA by YO-PRO, a broad-range bacterial probe, and a WD-
specific probe all colocalized to the same bacterial shapes. These
data and the absence of ambiguities in the PCR-based analysis
of broad-range bacterial 16S rDNA performed during the third
and 15th passages indicate that the cultures were not contam-
inated with other bacteria. Multiple FISH experiments clearly
showed small, rod-shaped bacteria, but the slender shapes and
the chainlike arrangement were not as well preserved as were
those seen in staining by YO-PRO. The different morphologies
seen by these 2 methods may arise from the different fixation
procedures (i.e., formalin vs. alcohol) and/or the additional
processing steps employed in the FISH protocol.
Uncertainty remains as to whether T. whipplei prefers in-
tra- or extracellular growth environments. A detailed electron-
microscopic study of intestinal WD [31] demonstrated that the
majority of morphologically intact bacteria were located extra-
cellularly in the lamina propria and that intracellular bacteria
were in various stages of degradation. These findings are con-
sistent with the results of more-recent work, which used FISH
in intestinal biopsies [21] and which found T. whipplei–rRNA
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Figure 4. Electron micrographs of Tropheryma whipplei in fibroblast cell culture after the 14th passage. A, Results of scanning electron microscopy
of strain TW08/27 (original magnification,20,000). B, Results of transmission electron microscopy of strain TW09/04 (original magnification,12,275).
hybridization signals, corresponding to metabolically active
bacteria, in the lamina propria, directly subjacent to the epi-
thelial basement membrane, but not inside cells. The location
of the rRNA signal did not correspond to the inclusions char-
acteristic of macrophages from patients with WD, inclusions
that PAS shows to be positive for T. whipplei. On the other
hand, Raoult et al. [10] reported intracellular growth in their
fibroblast cell–culture system, which used PAS and immuno-
fluorescence staining. In the present study, quantitative PCR
with supernatant and with combined fractions indicated that
T. whipplei grows in close association with fibroblasts but also
grows in the cell-free supernatant. SEM clearly showed bacteria
in extracellular locations (figure 4A); on the other hand, TEM
showed intact bacteria in both intra- and extracellular locations
(figure 4B). The host cells too appeared to be intact, and this
obvious lack of cell damage is reminiscent of the paucity, in T.
whipplei infection in humans, of both cell damage and inflam-
matory cellular infiltrate [16].
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The T. whipplei isolate TW08/27 has been subjected to com-
plete-genome sequencing [25] (see the http://www.sanger.ac
.uk/Projects/T_whipplei/ Web site). Among fastidious and cul-
tivation-resistant bacterial pathogens, the genome of T. whipplei
is the third to be sequenced, after those of Treponema pallidum
and Mycobacterium leprae. Although resistance to cultivation
is uncommon among known pathogenic bacteria, the vast ma-
jority of bacteria in natural environments and in the commensal
flora have not been cultivated in vitro [32, 33]. The extent to
which currently uncharacterized or uncultivated bacteria might
be involved in chronic idiopathic diseases is unclear [34]. In
this context, T. whipplei is an attractive model organism with
which to study such questions and, thus, to gather insight into
related, important biological principles.
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